Source comparison
PT-141 for Premature Ejaculation Research: Comparison
Primary Pathway Melanocortin receptor (MC3-R/MC4-R) activation in hypothalamus and spinal cord Serotonin reuptake inhibition at synaptic cleft, increasing 5-HT signalling Sodium channel blockade in penile mechanoreceptors PT-141 is the only investigational age
This comparison does not assign a generated winner or score.
- Primary Pathway
- Melanocortin receptor (MC3-R/MC4-R) activation in hypothalamus and spinal cord
- Serotonin reuptake inhibition at synaptic cleft, increasing 5-HT signalling
- Sodium channel blockade in penile mechanoreceptors
- PT-141 is the only investigational agent that modulates ejaculatory timing without reducing arousal or sensation
- Effect on Libido
- Pro-sexual. Enhances desire and motivation in preclinical models
- Anti-sexual. Reduced libido reported in 30–70% of users
- Neutral to negative. Reduced sensation may lower arousal
- SSRIs suppress libido systemically; PT-141 enhances it
- IELT Extension (Preclinical Data)
- 60–90% increase at 1.0–2.0 mg/kg subcutaneous in rodent models
- 200–300% increase (dapoxetine 30–60mg daily dosing in human trials)
- Variable. Depends on absorption and partner sensation tolerance
- SSRIs produce larger absolute IELT gains but with higher discontinuation due to side effects
- Route of Administration
- Subcutaneous injection or intranasal (investigational)
- Oral tablet (daily or on-demand)
- Topical spray or cream applied 10–30 minutes before intercourse
- Injection route limits spontaneity; intranasal formulations under development may improve adherence
- Onset of Action
- 30–60 minutes (subcutaneous); effects peak at 90–120 minutes
- 1–3 hours (dapoxetine on-demand); 2–4 weeks (daily SSRIs for steady-state)
- 10–30 minutes depending on formulation
- PT-141's onset is faster than daily SSRIs but slower than topical agents
- Sexual Side Effects
- Minimal. No anhedonia or orgasmic dysfunction reported in trials
- High. Delayed orgasm, anorgasmia, reduced sensation in 30–70%
- Moderate. Partner reports reduced sensation; potential for penile numbness
- PT-141 is unique in extending IELT without orgasmic blunting